AI-assisted, human-published
04/14/2026 /Funding Events
Adcendo Secures $75M in Series C Funding for Cancer Treatment Advancement
Biotech firm Adcendo successfully concludes a $75 million Series C financing round to advance antibody-drug conjugates for high unmet medical need cancers. Jeito Capital leads the financing round, emphasizing Adcendo's innovation and clinical development strategy.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com